title: [Incorrect about hormone treatment in prostatic cancer].
authors.forename: Sophie D
authors.initials: SD
authors.lastname: Fosså
authors.forename: Andrea
authors.initials: A
authors.lastname: Egey
authors.forename: Svein Andreas
authors.initials: SA
authors.lastname: Haukaas
authors.forename: Anders
authors.initials: A
authors.lastname: Angelsen
authors.forename: Olbjørn
authors.initials: O
authors.lastname: Klepp
authors.forename: Viktor
authors.initials: V
authors.lastname: Berge
authors.forename: Karol
authors.initials: K
authors.lastname: Axcrona
authors.forename: Wolfgang
authors.initials: W
authors.lastname: Lilleby
mesh_terms: D000726:Androgen Antagonists / Q000627:therapeutic use; D000813:Anilides / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D003131:Combined Modality Therapy; D006801:Humans; D008297:Male; D009570:Nitriles / Q000627:therapeutic use; D011471:Prostatic Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000628:therapy; D014105:Tosyl Compounds / Q000627:therapeutic use
chemical_list: D000726:Androgen Antagonists; D000813:Anilides; D000970:Antineoplastic Agents; D009570:Nitriles; D014105:Tosyl Compounds; C053541:bicalutamide